Selank + Semax is the descriptive name for a two-peptide research blend combining the canonical Russian-developed nootropic and anxiolytic peptides. Both components are registered pharmaceutical therapies in the Russian Federation, both were developed at the same Institute of Molecular Genetics, and both have substantive Russian-language clinical literature — an unusual combination of registered-pharmaceutical status and published trial data for this market. This monograph lays out the composition, what each component contributes, the published research record, and the relationship to the vendor-branded name "Adamax."
Composition.
The blend is sold at a 1:1 mass ratio in most vendor catalogues. Vial sizes vary; 10 mg total fill is the most common configuration. Some vendors sell Selank and Semax in a combined vial under the brand name "Adamax," but the true Adamax molecule is a single defined synthetic peptide (Ac-MEHFPGPAG-NH₂), not this two-component blend — see the Adamax monograph for the chemistry. The "Adamax = Selank + Semax" interpretation that appears in some vendor catalogues is incorrect; researchers should not treat the two as interchangeable.
What each component contributes.
Semax is a synthetic heptapeptide analog of the ACTH(4-10) fragment (Met-Glu-His-Phe-Pro-Gly-Pro). Its preclinical literature describes BDNF upregulation, TrkB-receptor sensitisation, dopaminergic-pathway effects, and neuroprotection in cerebral-ischaemia models. The registered Russian formulations target stroke recovery and cognitive-deficit research contexts. Selank is a synthetic heptapeptide analog of the immune-modulator tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro). Its characterisation focuses on GABAergic and serotonergic modulation with an anxiolytic profile that, unlike benzodiazepines, does not produce sedation, dependence, or cognitive impairment in published trials. The registered Russian indication is generalised anxiety disorder.
Research applications and the evidence base.
The combined blend has been used in preclinical and community research contexts for combined cognitive-and-anxiolytic questions, stress-resilience modelling, and post-injury CNS-recovery research. The individual component evidence base is unusually substantive for this market — both peptides have decades of Russian clinical trials, including controlled trials in stroke recovery (Semax), generalised anxiety (Selank), and attention-deficit research (Semax). Western Phase III trials of either component are absent, and the combined "Selank + Semax" formulation has no completed Phase III trial. Neuroimaging work has reported anatomically distinct effects — prefrontal-connectivity changes with Semax, amygdala-connectivity changes with Selank — which is the mechanistic basis for the "complementary brain systems" rationale.
No human clinical trial has established administration parameters for the Selank + Semax blend; VialTalk does not provide community-sourced dosing.
Research context.
Selank + Semax is the canonical nootropic-anxiolytic peptide stack in the research literature, and the reference combination for researchers studying combined cognitive-activation + stress-modulation in peptide pharmacology. The two registered Russian formulations are intranasal solutions; the lyophilized research-grade products sold in Western vendor catalogues are pharmacokinetically distinct and have not been characterised in registered trials in their injectable form.
Storage and handling.
Lyophilized vials should be kept refrigerated (2–8 °C) and protected from light. Both component peptides tolerate refrigerator-temperature storage reasonably well, but neither tolerates repeated freeze-thaw cycles. Intranasal administration — common in published Russian trials of the individual components — requires formulation pH and tonicity adjustment that the lyophilized research-grade vial does not provide.
Quality and COA considerations.
A meaningful COA must confirm identity for both peptides via mass spectrometry (Semax ~813 g/mol, Selank ~751 g/mol), per-component HPLC purity (≥98% benchmark), and a fill-weight breakdown confirming the labelled 1:1 ratio. Sequence-mislabelling between Semax and Selank, and confusion with adamantane-modified Semax derivatives (the true Adamax molecule), are known quality issues in this market. Sterility and endotoxin testing should be reported for any vial intended for injection-model use.
Research-use note: This monograph is an educational summary of the published research literature on the Selank + Semax blend. Both individual components are registered pharmaceuticals in the Russian Federation; neither has Phase III Western approval, and the combined blend has not been evaluated in completed Phase III trials. Nothing here is medical advice or a usage recommendation.
